BioMedNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) Closes $28.6M Private Placement to Fund Long-Term Operating Plan

(NetworkNewsWire via Comtex)

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has completed a private placement transaction resulting in aggregate gross proceeds of an estimated $28.6 million. After deducting placement agent fees and other offering expenses, capital from the transaction, along with existing balance sheet cash, will be used to fund DRIO's long-term strategic operating plan. "We are pleased to have the confidence of our largest shareholder and several new highly regarded healthcare investors as we expand our commercial to manage existing and anticipated near-term agreements with health care payers," said Dario CEO Erez Raphael, chief executive officer of Dario. "The adoption rate of digital therapeutics has been accelerated by the current pandemic. Dario's efficacious, value-oriented solution is well-positioned to compete in this largely untapped U.S. market."

To view the full press release, visit http://ibn.fm/utz7J

About DarioHealth Corp.

DarioHealth is a leading, global, digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. The company's cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario offers one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new geographic markets to address chronic conditions using a performance-based approach to improve the health of users managing chronic disease. For more information, visit the company's website at www.DarioHealth.com

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company's newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

comtex tracking